Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

PURPOSE: Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. METHODS: The study presented...

詳細記述

保存先:
書誌詳細
主要な著者: Wehler, Thomas C., Graf, Claudine, Möhler, Markus, Herzog, Jutta, Berger, Martin R., Gockel, Ines, Lang, Hauke, Theobald, Matthias, Galle, Peter R., Schimanski, Carl C.
フォーマット: Artigo
言語:Inglês
出版事項: Springer Berlin Heidelberg 2013
主題:
Original Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771414/
https://ncbi.nlm.nih.gov/pubmed/23918349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-013-1483-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料